2 news items
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
ATXI
FBIO
15 May 24
hydromorphone, a Schedule II opioid, for rescue of breakthrough pain. Avenue aims to initiate the Phase 3 safety study as soon as feasible. The Company
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
ATXI
FBIO
18 Mar 24
supervised setting. The final non-inferiority study is designed to assess the theoretical risk of opioid-induced respiratory depression related to opioid
- Prev
- 1
- Next